We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Paratek's (PRTK) NDAs for Omadacycline Get Priority Review
Read MoreHide Full Article
Paratek Pharmaceuticals, Inc. announced that the FDA has accepted two new drug applications (NDAs), seeking approval of its antibiotic candidate, omadacycline. The NDAs were granted priority review, thus speeding up the review process. A decision is expected in October 2018.
The NDAs are seeking approval of once-daily oral and intravenous ("IV") dosing of omadacycline for treating community-acquired bacterial pneumonia (“CABP”) and acute bacterial skin and skin structure infections (“ABSSSI”).
The candidate already enjoys Qualified Infectious Disease Product and Fast Track designation for both the indications.
Shares of the company were up almost 3% in after-market trading on Apr 4. However, Paratek’s shares have declined 25.7% so far this year, underperforming the industry’s decline of 7.4% in the said period.
The NDAs submitted included positive data from phase III program evaluating omadacycline in ABSSSI and CABP patients. The candidate was also well tolerated.
In April 2017, Paratek had announced non-inferiority of omadacycline to Bayer’s (BAYRY - Free Report) CABP drug, Avelox, in a phase III study.
The chief medical officer of Paratek stated that resistance to antibiotics is on the rise, increasing the need for new antibiotics.
Paratek is also planning to file a marketing authorization in the European Union for omadacycline in similar indications.
The candidate is also being developed for the treatment of urinary tract infections.
However, there are approved therapies available for the treatment of CABP and ABSSSI, which includes Allergan plc’s Teflaro. Moreover, Nabriva Therapeutics plc is evaluating its antibiotic candidate lefamulin in late stage studies in CABP and ABSSSI.
Apart from omadacycline, Paratek’s acne candidate, Seysara, is under review in the United States.
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Paratek's (PRTK) NDAs for Omadacycline Get Priority Review
Paratek Pharmaceuticals, Inc. announced that the FDA has accepted two new drug applications (NDAs), seeking approval of its antibiotic candidate, omadacycline. The NDAs were granted priority review, thus speeding up the review process. A decision is expected in October 2018.
The NDAs are seeking approval of once-daily oral and intravenous ("IV") dosing of omadacycline for treating community-acquired bacterial pneumonia (“CABP”) and acute bacterial skin and skin structure infections (“ABSSSI”).
The candidate already enjoys Qualified Infectious Disease Product and Fast Track designation for both the indications.
Shares of the company were up almost 3% in after-market trading on Apr 4. However, Paratek’s shares have declined 25.7% so far this year, underperforming the industry’s decline of 7.4% in the said period.
The NDAs submitted included positive data from phase III program evaluating omadacycline in ABSSSI and CABP patients. The candidate was also well tolerated.
In April 2017, Paratek had announced non-inferiority of omadacycline to Bayer’s (BAYRY - Free Report) CABP drug, Avelox, in a phase III study.
The chief medical officer of Paratek stated that resistance to antibiotics is on the rise, increasing the need for new antibiotics.
Paratek is also planning to file a marketing authorization in the European Union for omadacycline in similar indications.
The candidate is also being developed for the treatment of urinary tract infections.
However, there are approved therapies available for the treatment of CABP and ABSSSI, which includes Allergan plc’s Teflaro. Moreover, Nabriva Therapeutics plc is evaluating its antibiotic candidate lefamulin in late stage studies in CABP and ABSSSI.
Apart from omadacycline, Paratek’s acne candidate, Seysara, is under review in the United States.
Paratek Pharmaceuticals, Inc. Price
Paratek Pharmaceuticals, Inc. Price | Paratek Pharmaceuticals, Inc. Quote
Zacks Rank
Paratek has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>